Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus
Table 5
Adverse prognostic factors identified by multivariate analysis in patients with relapsed/refractory myeloma treated with lenalidomide and dexamethasone.
PFS: progression-free survival; TTP: time to progression; RRMM: relapsed or refractory multiple myeloma; Len/Dex: lenalidomide combined with dexamethasone; LDH: lactate dehydrogenase; ISS: international staging system.